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Abstract: Pericytes are peri-vascular mural cells which have an important role in the homeostatic
regulation of inflammatory and angiogenic processes. Flightless I (Flii) is a cytoskeletal protein
involved in regulating cellular functions, but its involvement in pericyte activities during wound
healing is unknown. Exacerbated inflammation and reduced angiogenesis are hallmarks of impaired
diabetic healing responses, and strategies aimed at regulating these processes are vital for improving
healing outcomes. To determine the effect of altering Flii expression on pericyte function, in vitro
and in vivo studies were performed to assess the effect on healing, inflammation and angiogenesis
in diabetic wounds. Here, we demonstrated that human diabetic wounds display upregulated
expression of the Flii protein in conjunction with a depletion in the number of platelet derived growth
factor receptor β (PDGFRβ) +/ neural glial antigen 2 (NG2) + pericytes present in the dermis. Human
pericytes were found to be positive for Flii and attenuating its expression in vitro through siRNA
knockdown led to enhanced proliferation, migration and angiogenic functions. Genetic knockdown
of Flii in a streptozotocin-induced murine model of diabetes led to increased numbers of pericytes
within the wound. This was associated with dampened inflammation, an increased rate of angiogenic
repair and improved wound healing. Our findings show that Flii expression directly impacts pericyte
functions, including proliferation, motility and angiogenic responses. This suggests that Flii regulation
of pericyte function may be in part responsible for the changes in pericyte-related processes observed
in diabetic wounds.
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1. Introduction
Diabetes is a debilitating disease which manifests in many pathologies including retinopathy,
neuropathy and delayed cutaneous wound repair [1]. Impaired healing often leads to the development
of chronic wounds in diabetic patients, the most common type being diabetic foot ulcers (DFUs) [2].
DFUs are characterised by poor vascularisation and an exacerbated inflammatory response which fails
to resolve appropriately [3].
Int. J. Mol. Sci. 2020, 21, 5599; doi:10.3390/ijms21165599 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 5599 2 of 15
Pericytes are peri-vascular mesenchymal stem cell (MSC)-like cells involved in the regulation
of both vascularisation and inflammation [4,5]. In diabetic patients, many tissues exhibit a decrease
in pericyte populations, and this reduction has been implicated in the progression of some diabetic
pathologies [6]. Given that pericyte depletion is observed in the skeletal muscle of diabetic feet [7],
it is possible that pericytes may also play a role in contributing to the delayed cutaneous healing
experienced by diabetic patients.
Flightless I (Flii) is a member of the gelsolin family of cytoskeletal proteins that regulate actin by
severing pre-existing filaments and/or capping filament ends to enable filament reassembly into new
cytoskeletal structures. Flii is involved in numerous cellular activities including regulating transcription
via co-activation of nuclear hormone receptors [8,9] and regulation ofβ-catenin-dependent transcription.
Flii contains a leucine-rich repeat region (LRR) which allows this protein to play an additional role in
the mediation of cell signalling events [10]. Studies have shown that Flii acts as a negative regulator
of wound healing [11]. Genetic knockdown of Flii leads to enhanced proliferation and migration of
keratinocytes and fibroblasts, resulting in accelerated re-epithelialisation and contraction of acute
wounds [12]. Flii attenuation has been explored as a therapeutic approach to repair, and treatment of
wounds with a Flii neutralising antibody (FnAb) improves healing in murine and porcine models of
acute cutaneous repair [12,13].
We have previously found that Flii negatively impacts healing in a streptozotocin (STZ)-induced
murine model of type 1 diabetes [14]. Flii-attenuated diabetic wounds exhibit enhanced expression of
some angiogenic markers, however the mechanisms leading to this have not been identified. In this
study, the STZ-induced model of type 1 diabetes is again used as treated mice exhibit symptoms of
human type 1 diabetes with chronic pancreatic islet inflammation, insulin deficiency and impaired
wound healing [15]. Given the importance of pericyte participation for normal vascular repair, and the
lack of pericytes observed in human diabetic patients, we aimed to investigate whether altered pericyte
function underpins Flii effects on diabetic wound healing.
2. Results
2.1. Flightless I Expression Impacts Human Pericyte Function
Platelet derived growth factor receptor β (PDGFRβ)/neural glial antigen 2 (NG2) dual staining
was carried out in 4 µm sections of paraffin-embedded human samples of acute wounds and diabetic
wounds. Wound-resident PDGFRβ+/NG2+ pericytes were counted and normalised to wound area for
each wound. Pericytes were observed in all wounds, however pericyte numbers were significantly
lower in diabetic than in acute wound samples (Figure 1a,c). Immunohistochemical analysis of Flii
expression in human wound samples showed a strong trend towards increased Flii expression in
diabetic wounds when compared to acute wounds, although this difference was not statistically
significant (p = 0.0724). As such, pericyte numbers in the human wounds examined displayed an
inverse relationship with Flii expression, supporting the notion that Flii expression may have a negative
impact on wound healing by affecting the functionality and survival of wound-resident pericytes
during diabetic healing (Figure 1b,d).
In order to directly investigate the impact of Flii expression on pericyte function, it was necessary
to knock down Flii expression in human pericytes for use in functional assays. SiRNA knockdown of
Flii was carried out in pericytes. Immunocytochemical staining and Western blotting of lysates from
untreated, siControl-treated and siFlii-treated human pericytes from placenta (hPC-PL) indicated that
human pericytes (hPC-PL) expressed Flii in culture, and siRNA knockdown of Flii induced markedly
decreased levels of Flii protein expression after 48 h (Figure 2a,b). Proliferation and migration rates of
untreated, siControl-treated and siFlii-treated hPC-PL were assessed with a WST1 assay and scratch
assay, respectively. Attenuation of Flii led to accelerated proliferation (Figure 2c) and migration
(Figure 2d,e) of pericytes when compared to untreated and siControl-treated cells (n = 6).
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Figure 1. (a) Dual Platelet derived growth factor receptor β (PDGFRβ)/neural glial antigen 2 (NG2) 
pericyte staining in 4 μm sections of paraffin-embedded acute and diabetic human wounds, scale bar 
= 50 μm. (b) Immunohistochemical detection of Flightless I (Flii) in corresponding 4 μm sections of 
paraffin-embedded acute and diabetic human wounds, scale bar = 100 μm. Composite images 
captured at 20× objective. Graphical data of (c) the number of pericytes per mm2 within acute and 
diabetic human wounds and (d) the expression levels of Flii in acute and diabetic human wounds. *= 
p < 0.05. 
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Figure 1. (a) Dual Platelet derived growth factor receptor β (PDGFRβ)/neural glial antigen 2 (NG2)
pericyte staining in 4 µm sections of paraffin-embedded acute and diabetic human wounds, scale
bar = 50 µm. (b) Immunohistochemical detection of Flightless I (Flii) in corresponding 4 µm sections of
paraffin-embedded acute and diabetic human wounds, scale bar = 100 µm. Composite images captured
at 20× objective. Graphical data of (c) the number of pericytes per mm2 within acute and diabetic
human wounds and (d) the expression levels of Flii in acute and diabetic human wounds. * = p < 0.05.
2.2. Flii Expression and Diabetic Status both Negatively Impact Dermal Pericyte Numbers In Vivo
PDGFRβ/NG2 co-localisation was used to quantify pericyte numbers in unwounded skin of
non-diabetic an diabet c Flii+/−, WT and FliiTg/Tg mice (Figure 3a). Flii expression negatively impacted
pericyte presence in unwounded skin, with non-diabetic Flii+/− and FliiTg/Tg kin displaying increased
and decreas pericyte numbers respectively, when compared to WT mice (Figure 3b) (n = 8). In all
three g notypes, a period of prolonged hyperglycaemia (>6 we ks) resulted i significant depletion of
pericyte numbers in unwounded skin when compared to no -diabetic s in of the same genotype.
2.3. Increased Pericyte Numbers in Flii+/− Diabetic Skin are Associated with an Increased Capacity for Healing
Flii+/− wounds displayed an increase in the number of wound-resident PDGFRβ+/NG2+ pericytes
(Figure 3c) (n = 8). In contrast, FliiTg/Tg wounds exhibited a diminished capacity for the recruitment
of pericytes to the wound bed. These pericyte numbers correlated positively with diabetic healing
rates. Macroscopically (Figure 3d), wound area decreased more rapidly in pericyte-rich Flii-attenuated
wounds and was delayed in Flii overexpressing wounds (Figure 3e). Histological measurements of
hematoxylin and eosin-stained sections (Supplementary Figure S1a) revealed that wound closure and
re-epithelialisation displayed similar trends (Supplementary Figure S1b,c).
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Figure 2. (a) Flii knockdown by siRNA as shown by Western Blotting of untreated, siControl- and 
siFlii-treated human pericytes from placenta (hPC-PL) cell lysates 48 hours after knockdown. (b) Flii 
knockdown by siRNA as shown by immunocytochemical staining of untreated, siControl- and siFlii-
treated hPC-PL cells 48 hours after knockdown. No primary antibody-treated hPC-PL cells are shown 
as control. Images taken at 40× objective, scale bar = 20 μm. (c) Effect of Flii knockdown on hPC-PL 
proliferation in a WST1 proliferation assay. Data displayed as mean ± SEM, n = 6. Results are 
representative of three independently conducted experiments. (d) Effect of Flii knockdown on hPC-
PL migration in a scratch wound assay. Data displayed as mean ± SEM, n = 6. Results are 
representative of three independently conducted experiments. (e) Images representative of untreated, 
siControl-treated and siFlii-treated hPC-PL scratch wounds at 0, 6, 12, 18, 24 and 48 hours. Images 
Figure 2. (a) Flii knockdown by siRNA as shown by Western Blotting of untreated, siControl- and
siFlii-treated human pericytes from placenta (hPC-PL) cell lysates 48 h after knockdown. (b) Flii
knockdown by siRNA as shown by immunocytochemical staining of untreated, siControl- and
siFlii-treated hPC-PL cells 48 h after knockdown. No primary antibody-treated hPC-PL cells are
shown as control. Images taken at 40× objective, scale bar = 20 µm. (c) Effect of Flii knockdown on
hPC-PL proliferation in a WST1 proliferation assay. Data displayed as mean ± SEM, n = 6. Results
are representative of three independently conducted experiments. (d) Effect of Flii knockdown on
hPC-PL migration in a scratch wound assay. Data displayed as mean ± SEM, n = 6. Results are
representative of three independently conducted experi ents. (e) Images representative of untreated,
siControl-treated and siFlii-treated hPC-PL scratch wounds at 0, 6, 12, 18, 24 and 48 h. Images taken at
4× objective, scale bar = 300 µm. Statistical significance was calculated using a two-way analysis of
variance (ANOVA) where * = p < 0.05, *** = p < 0.001, **** = p < 0.0001.
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skin of Flii+/−, WT and FliiTg/Tg wounds. Data displayed as mean ± SEM, n = 6. (c) PDGFRβ/NG2+ 
pericyte numbers in diabetic Flii+/−, WT and FliiTg/Tg wounds. Data displayed as mean ± SEM, n = 8. (d) 
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= 5 mm. (e) Macroscopic wound area of Flii+/−, WT and FliiTg/Tg diabetic excisional wounds. Data 
Figure 3. (a) Dual PDGFRβ/NG2 pericyte staining in 4 µm sections of paraffin-embedded murine
tissue. No primary antibody-stained section is shown as control. Composite images taken at 20×
objective, scale bar = 20 µ . (b) PDGFRβ/NG2+ pericyte numbers in acute and diabetic unwounded
skin of Flii+/−, WT an liiTg/Tg wounds. Data displayed as mean ± SEM, n = 6. (c) PDGFRβ/NG2+
pericyte numbers in di l i+/−, WT and FliiTg/Tg wounds. Data displayed as mea ± SEM, n = 8.
(d) Flii+/−, WT and FliiTg/Tg diabetic excisional woun s collected at 3, 5, 7 and 14 days post-injury.
Scale bar = 5 mm. (e) Macroscopic wound area of Flii+/−, WT and FliiTg/Tg diabetic excisional wounds.
Data displayed at mean ± SEM, n = 8. Statistical significance was calculated using a two-way ANOVA
where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
2.4. Flii Attenuation and the Resultant Increase in Pericyte Numbers are Associated with
Dampened Inflammation
Anti-Neutrophil antibody (NIMP-R14) staining revealed that neutrophil infiltration was
significantly decreased at days 3 and 5 of healing in pericyte-rich Flii+/− wounds, while the low
pericyte numbers of FliiTg/Tg wounds coincided with an exacerbated neutrophil presence in the wound
bed at days 3, 5 and 7 (Figure 4a) (n = 7). Likewise, the presence of F4/80+ macrophages was decreased
in Flii+/− wounds at day 7 and increased in FliiTg/Tg wounds at days 5 and 7 (Figure 4b) (n = 7).
The expression of pro-inflammatory cytokine tumour necrosis factor (TNF) in Flii+/− wounds peaked at
day 3 before rapidly resolving over the course of healing, while FliiTg/Tg wounds displayed prolonged
and elevated TNF expression, which was not resolved by day 14 (Figure 4c). This, in conjunction with
an increased abundance of anti-inflammatory interleukin-10 (IL-10)-expressing cells in Flii+/− wounds
Int. J. Mol. Sci. 2020, 21, 5599 6 of 15
(Figure 4d), suggests that Flii-attenuated, pericyte-rich wounds display a rapid and efficient period of
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The enhanced pericyte presence in Flii+/− wounds corresponded with increased vascular 
endothelial growth factor (VEGF) signalling at days 5 and 7. In contrast, FliiTg/Tg wounds showed 
delayed upregulation of VEGF which did not increase until day 14 of healing (Figure 5a). Increased 
VEGF expression in Flii+/− wounds was associated with enhanced revascularisation of the wound bed, 
as increased CD31 (endothelial cell marker) was observed in the tissue at days 5, 7 and 14. FliiTg/Tg 
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Figure 4. (a) Immunohistochemical detection and quantification of Anti-Neutrophil antibody
(NIMP-R14) in 4 µm secti ns of paraffin-embed ed diabetic Flii+/−, WT and FliiTg/Tg wounds. Images
taken at 40x objective, scale bar = 20µm. Data displayed as mean± SEM, n = 7. (b) Immunohistochemical
detection and quantification of F4/80 in 4 µm sections of paraffin-embedded diabetic Flii+/−, WT and
FliiTg/Tg wounds. Images taken at 40× objective, scale bar = 20 µm. Data displayed as mean ± SEM,
n = 7. (c) Immunohistochemical detection and quantification of tumour necrosis factor (TNF) in 4 µm
sections of paraffin-embedded diabetic Flii+/−, WT and FliiTg/Tg wounds. Images taken at 20× objective,
scale bar = 50 µm. Data displayed as mean ± SEM, n = 7. (d) Immunohistochemical detection and
quantification of interleukin-10 (IL-10) in 4 µm sections of paraffin-embedded diabetic Flii+/−, WT and
FliiTg/Tg wounds. Images taken at 40× objective, scale bar = 20 µm. Data displayed as mean ± SEM,
n = 7. Statistical significance was calculated using a two-way ANOVA where * = p < 0.05, ** = p < 0.01,
*** = p < 0.001, **** = p < 0.0001.
2.5. Flii Attenuation and the Resultant Increase in Pericyte Numbers are Associated with Enhanced
Angiogenesis, Collagen Deposition and Remodelling
The enhanced pericyte presence in Flii+/− wounds corresponded with increased vascular
endothelial growth factor (VEGF) signalling at days 5 and 7. In c trast, FliiTg/Tg wounds showed
d layed upre ulation of VEGF which did ot increa e until day 14 of healing (Figure 5a). Increased
VEGF xpression in Flii+/− wounds was associated with e hanced revascu arisation of the wound bed,
as increased CD31 (endothelial cell marker) was observed in the tis ue t days 5, 7 and 14. FliiTg/Tg
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mice displayed a decreased capacity to rebuild vascular structures, as revascularisation of the slow
healing FliiTg/Tg wounds by day 14 only reached levels similar to those reached by the Flii+/− wounds
within the first week of healing (Figure 5b) (n = 7).
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Figure 5. (a) Immunohistochemical detection and quantification of vascular endothelial growth factor
(VEGF) in 4 µm sections of paraffin-embedded diabetic Flii+/−, WT and FliiTg/Tg wounds. Images taken
at 20× objective, scale bar = 50 µm. Data displayed as mean ± SEM, n = 7. (b) Immunohistochemical
detection and quantification of CD31 in 4 µm sections of paraffin-embedded diabetic Flii+/−, WT and
FliiTg/Tg wounds. Images taken at 20× objective, scale bar = 50 µm. Data displayed as mean ± SEM,
n = 7. (c) Representative images of tube formation in HDMECs alone and HDMECs co-cultured with
hPC-PLs, siControl hPC-PLs, siFlii hPC-PLs and hPC-PL CM at 6, 24, 48 and 72 h. Images taken at 4×
objective, scale bar = 200 µm. (d) Effect of untreated, siControl-treated or siFlii-treated hPC-PLs on
human dermal microvascular endothelial cells (HDMECs) and (e) Effect of hPC-PL CM or hPC-PL
co-culture on HDMEC sprouting in a matrigel tube formation assay. All data displayed as mean ± SEM,
n = 5. Results representative of three independently conducted experiments. Statistical significance
calculated by two-way ANOVA, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
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In vitro, human dermal microvascular endothelial cells (HDMECs) cultured with hPC-PLs formed
increased numbers of tube-like structures with greater structural integrity than those formed by
HDMECs alone. HDMECs co-cultured with siFlii hPC-PLs formed significantly increased numbers of
tubes, and these structures lasted significantly longer in culture than those formed by HDMECs cultured
with untreated or siControl-treated hPC-PLs (n = 5). Culturing of HDMECs alone in endothelial
medium conditioned by hPC-PLs (hPC-PLs CM) (n = 6) led to increased tube formation, however these
structures displayed more rapid degradation than any other treatment group (Figure 5c–e).
Collagen deposition and remodelling is important in the determination of scar formation after
healing. Collagen I levels in Flii+/− diabetic wounds were significantly decreased compared to WT
wounds, and significantly increased in FliiTg/Tg wounds at day 14 (Supplementary Figure S2a). The level
of collagen III was also increased in FliiTg/Tg wounds at day 14 (Supplementary Figure S2b), indicating
more rapid deposition of collagens overall when Flii levels are increased.
3. Discussion
Pericyte depletion is documented in a number of diabetic tissues, and the low numbers of
these important cells in the dermis of the skin may adversely affect the regulation of inflammation
and vascular processes. Staining for specific markers of pericytes revealed that diabetic wounds
contained significantly fewer pericytes in the dermis than acute wounds from healthy patients. Diabetic
wounds also exhibited increased expression of Flii, a known negative regulator of cutaneous healing.
This indicates an inverse relationship between Flii expression and pericyte presence and suggests a role
for Flii in the regulation of pericyte behaviour. In an inducible murine model of type 1 diabetes carried
out in mice expressing differential levels of Flii expression, pericyte numbers were highest in Flii+/−
wounds and lowest in FliiTg/Tg wounds when compared to WT, reiterating the inverse relationship
between Flii expression and pericyte numbers observed in human samples.
Flii attenuation in vitro led to increased proliferation and migration of pericytes. This may explain
the increased pericyte numbers found residing basally in Flii+/− skin and the apparent enhanced
capacity of Flii+/− skin to recruit pericytes to wounds during healing. The increased pericyte numbers
in Flii-attenuated skin were also associated with an enhanced capacity for healing. Zhuang et al. [16]
have previously demonstrated that pericytes in the dermis encourage basal keratinocytes, via BMP-2
signalling, to undergo increased planar cell divisions leading to faster maturation of the epithelial layer.
While re-epithelialisation was only mildly accelerated in Flii+/− wounds, this is consistent with the
increased pericyte numbers observed in the dermis of these mice.
Pericyte-rich Flii+/− wounds displayed dampened infiltration of neutrophils, while FliiTg/Tg
wounds exhibited a heightened and prolonged neutrophil response. This amplified neutrophil
infiltration in FliiTg/Tg wounds is reminiscent of the elevated neutrophil infiltrate often observed
in human chronic wounds. The cytoskeletal relaxation of pericytes on the abluminal surface of
blood vessels is required for the opening of gaps termed ‘low expression regions’ (LERs) between
pericytes, which allow for neutrophil passage through the endothelial and sub-endothelial layers of the
vessel wall [17]. This pericyte relaxation is mediated by Rho/ROCK signalling, whereby neutrophils
cause inhibition of the Rho/ROCK pathway in pericytes, leading to suppression of actomyosin-based
contractility [18]. It has been shown that Flii does not modulate Rho/ROCK signalling, but does
regulate actin cytoskeletal remodelling through a Rac-1-dependent pathway [19]. Therefore, dampened
neutrophil infiltration in Flii+/− wounds may be two-fold: there are more pericytes present in these
wounds to cover the abluminal surface of vessels and prevent vascular leakage, and Flii attenuation in
those pericytes may additionally impact neutrophil infiltration by altering pericyte contractility.
Macrophage recruitment was also diminished in Flii-attenuated wounds. This may be partly due
to the decreased presence of neutrophils in the granulation tissue which release chemokines to attract
macrophages [20]. In Flii overexpressing wounds, macrophage infiltration was aggravated, echoing
the exacerbated inflammatory status of human chronic wounds. Flii expression correlated with an
inflammatory cytokine profile within the diabetic wounds, as increased IL-10-expressing cells were
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present in Flii+/− wounds. This coincided with rapidly resolving TNF expression, while in contrast,
FliiTg/Tg wounds displayed delayed upregulation of TNF which did not resolve within 14 days.
In models of inducible diabetes, both TNF-deficient mice and mice treated with a TNF inhibitor
exhibit significantly less pericyte apoptosis than control diabetic mice, implicating TNF expression
in mechanisms of pericyte depletion [21]. Decreased pericyte numbers in FliiTg/Tg wounds were
associated with a significant upregulation of TNF expression within the wound bed, which may
explain pericyte depletion in diabetic wounds with high Flii expression. TNF is a potent neutrophil
chemoattractant, facilitating neutrophil extravasion by signalling for the upregulation of adhesion
molecules on endothelial cells [22]. This may also contribute to the heightened neutrophil extravasion
observed in FliiTg/Tg wounds.
Increased pericyte numbers in Flii+/− wounds were associated with an enhanced capacity for
revascularisation of the wounded tissue after injury. This was demonstrated by increased CD31
expression in Flii+/− wounds and was mirrored by significantly decreased expression in FliiTg/Tg
wounds. These changes were accompanied by upregulation and downregulation of VEGF signalling
within Flii+/− and FliiTg/Tg wounds, respectively. Co-culture of mesenchymal and endothelial cells
induces differentiation of the mesenchymal cells to a pericyte-like phenotype and causes upregulation of
VEGF expression [23]. Pericyte-derived VEGF has therefore been suggested to mediate the endothelial
proliferation and migration necessary for neo-angiogenesis and endothelial cell survival. This is
consistent with the increased VEGF levels observed in pericyte-rich Flii+/− diabetic wounds.
Pericyte regulation of endothelial function is both physical and paracrine. In vitro formation
of angiogenic “tubes” by endothelial cells was increased in the presence of pericytes, and these
pericyte-supported tubes displayed enhanced stability. When Flii was attenuated in pericytes,
significantly more tubes formed and these structures degraded less rapidly, confirming that Flii
negatively effects pericyte contributions to angiogenesis. While the presence of pericyte-conditioned
medium was sufficient to enhance early endothelial sprouting, these vessels collapsed quickly,
illustrating that the physical presence of pericytes is necessary to provide support and longevity.
4. Materials and Methods
4.1. Human Samples
The collection of human skin samples was approved by the Human Research Ethics Committee
(TQEH/LMH/MH) (HREC/12/TQEHLMH/107/EXT01 Approved 30/5/2014) and was carried out in
accordance with the Declaration of Helsinki (1964). Prior to the collection of tissue samples, informed
consent was obtained from each patient. After an application of local anaesthetic, one 6 mm wound
biopsy was taken from around the edge of the wound of 6 patients with diabetic ulcers (ulcer duration
≥ 6 weeks; 4 men and 2 women with a mean age of 64 years) and 6 non-diabetic patients with acute
wounds (wound duration ≤ 4 weeks; 4 women and 2 men with a mean age of 40 years). Wound
samples were fixed in formalin and processed for immunohistological assessment.
4.2. Animal Studies
All transgenic mice were sourced from an in-house breeding colony, under approval from
the Women’s and Children’s Health Network Animal Ethics Committee (AE1055/11/19 Approved
06/12/2016). All mice were congenic on a BALB/c background. Flii overexpressing mice, which are
homozygous for a human Flii transgene in addition to the two endogenous copies of murine Flii,
were designated “FliiTg/Tg”. The generation of these mice has been previously described [24]. Mice with
a heterozygous Flii knockout were designated “Flii+/−”. The generation of this strain has also been
previously described [25]. Wild-type litter mates from this line (designated “WT”) were used as
controls for both strains.
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4.3. Murine Model of Inducible Diabetes
All animal procedures were approved by the Women’s and Children’s Health Network Animal
Ethics Committee (AE1021/10/2018 Approved 14/10/2018) and were carried out in accordance with
the Australian Code for the care and use of animals for scientific purposes. Diabetes was induced in
12-week-old female Flii+/−, WT and FliiTg/Tg mice with body weights of 18–22 g by STZ (Sigma-Aldrich,
Darmstadt, Germany) intraperitoneal injection, as described previously [14], and in more detail in the
Appendix A. Diabetes was confirmed by verification of a consistently elevated (>15.25 mg/L) blood
glucose level (BGL) for a sustained period of >6 weeks. A 50% rate of successful diabetic induction was
expected based on the literature and previous trials conducted. This was observed in the WT cohort
(53% induction), however Flii+/−mice exhibited an increased susceptibility to induction (76% induction),
while FliiTg/Tg mice displayed a decreased susceptibility to the development of diabetes in response to
STZ treatment (39% induction). Mice that were confirmed to be diabetic were subjected to a model of
excisional punch biopsy as described previously [26] and wounds were collected 3, 5, 7 or 14 days
post-surgery. Wound samples were fixed in 10% neutral buffered formalin overnight, transferred to
70% ethanol for 24 h, embedded in paraffin wax and sectioned for analysis.
4.4. Histological and Immunohistochemistry Assessment of Wounds
4 µm wound sections were dewaxed in xylene and brought to water through ethanol to allow
staining with Hematoxylin and Eosin, as described previously [27]. Wound sections were dewaxed in
xylene and brought to water in ethanol for immunohistochemical staining, as described previously [28].
Tissue sections were blocked in 3% blocking serum for 30 min at room temperature and incubated
with Flightless I (1 µg/mL, sc-21716, Santa Cruz Biotechnology, Dallas, TX, USA), β-tubulin (10 µg/mL,
T8328, Sigma-Aldrich, Castle Hill, NSW, Australia), NG2 (5 µg/mL, AB5320, Merck, Bayswater,
VIC, Australia), PDGFRβ (1 µg/mL, AF1042, R&D Systems, Minneapolis, MN, USA), collagen I
(5 µg/mL, 600-401-103-0.5, Rockland Immunochemicals, Gilbertsville, PA, USA), collagen III (5 µg/mL,
600-401-105-0.5, Rockland Immunochemicals, Gilbertsville, PA, USA), NIMP-R14 (0.5 µg/mL, sc-59338,
Santa Cruz Biotechnology, Dallas, TX, USA), F4/80 (5 µg/mL, MCA4975, Bio-Rad, Gladesville, NSW,
Australia), TNF (0.5 µg/mL, sc-52746, Santa Cruz Biotechnology, Dallas, TX, USA), IL-10 (2.5 µg/mL,
ab9969, Abcam, Cambridge, UK), CD31 (0.2 µg/mL, ab28364, Abcam, Cambridge, UK) or VEGF
(5 µg/mL, ab46154, Abcam, Cambridge, UK) antibodies overnight at 4 ◦C. Tissue sections were
subsequently incubated with secondary goat anti-rabbit Alexa Fluor 594 (A11011), goat anti-rat Alexa
Fluor 488 (A11006), goat anti-mouse Alexa Fluor 633 (A21050), goat anti-mouse Alexa Fluor 594 (A11004),
goat anti-mouse Alexa Fluor 488 (A11006) or donkey anti-goat Alexa Fluor 633 (A21082) (5 µg/mL,
Invitrogen, Carlsbad, CA, USA). Image analysis was performed using CellSens Imaging Software
to measure either positive cells per area or mean fluorescence intensity, which was automatically
calculated as intensity per area.
4.5. hPC-PL Culture and siFlii Knockdown
Human pericytes from placenta (hPC-PL) were purchased and cultured in Human Pericyte
Media as per company instructions (Promocell, Heidelberg, Germany). Transfection of siFlii
(GCUGGAACACUUGUCUGUGdTdT, CACAGACAAGUGUUCCAGCdTdT) or siControl
(GGUUAGCCGCACGUUAGUUdTdT, AACUAACGUGCGGCUAACCdTdT) constructs
(Sigma-Aldrich, Darmstadt, Germany) was carried out in suspension using Lipofectamine
2000 (ThermoFisher Scientific, Waltham, MA, USA), as described previously [29].
4.6. Immunocytochemistry
Untreated, siFlii-treated and siControl-treated hPC-PL were seeded at 1 × 104 cells/well in a
black 96-well plate (Corning, NY, USA) and incubated for 48 h. Cells were fixed in ice-cold methanol,
permeabilised with 0.5% Tween20, blocked with 3% normal goat serum and incubated with primary
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antibody (Flightless I and β-tubulin) for 2 h at room temperature. Cells were washed and incubated
with secondary antibody for 1 h, stained for 5 min with 1:5000 DAPI (4′,6-diamidino-2-phenylindole),
retained in phosphate buffered saline (PBS) and imaged using CellSens software. Results were
representative of three independent experiments with six technical replicates per experiment.
4.7. Proliferation
24 h after knockdown, untreated, siFlii-treated and siControl-treated hPC-PL were seeded at 5 ×
103 cells/well in a 96-well plate and allowed to adhere. After 6 h, 15 µl WST1 reagent (Sigma-Aldrich,
Darmstadt, Germany) was added to each well and incubated for 30 min at 37 ◦C. Absorbance at 620 nm
was read and subtracted from absorbance at 460 nm, after which the plate was discarded. WST1
incubation and absorbance measurements were repeated on duplicate plates at 24 and 48 h. Results
are representative of three independent experiments with six technical replicates per experiment.
4.8. Migration
12 h after knockdown, untreated, siFlii-treated and siControl-treated hPC-PL were seeded at 2 ×
104 cells/well in a 96-well plate and incubated for 12 h. Wells were “scratched” with a WoundMaker™
(Essen BioScience, Ann Arbor, MI, USA), washed once with PBS and the media was replaced. Scratches
were imaged at 0, 3, 6, 9, 12, 18, 24 and 48 h and the mean scratch width for each group was calculated
using CellSens software. Results were representative of three independent experiments with six
technical replicates per experiment.
4.9. Angiogenesis
24 h after knockdown, untreated, siFlii-treated and siControl-treated hPC-PL were seeded in
reduced growth factor matrigel (Corning, NY, USA) in a 15-well angiogenesis plate (ibidi GmbH, Bavaria,
Germany) with human dermal microvascular endothelial cells (HDMECs) (Promocell, Heidelberg,
Germany) at a ratio of 1:10. Cells were imaged at 0, 3, 6, 9, 12, 24, 36, 48 and 72 h and blinded analysis
of the number of tubes formed was calculated for each well using CellSens software. Results are
representative of three independent experiments with five technical replicates per experiment.
4.10. Western Blotting
Western blot analysis of Flii protein expression was carried out as described previously [28]
on hPC-PL cell lysates 48 h after siRNA treatment. Protein samples were made up to 15 uL and
3 uL of 5× SDS PAGE loading buffer (25 nM Tris pH 6.8, 8% glycerol, 1% SDS, 0.02% bromophenol
blue, 5% 2-mercaptoethanol) was added to each sample. Samples were boiled for 5 min at 100 ◦C to
denature, condensation was centrifuged, and samples were vortexed immediately prior to loading.
Prepared lysates were loaded at 15 µL/1.5 mm well in a polyacrylamide gel of appropriate percentage
(10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)) for the resolution and
visualisation of Flightless I protein. Electrophoresis was performed in 1×Western Running Buffer
at 25 mA per gel until the dye front approached the bottom of the gel. Transfer sponges, Whatman
paper and nitrocellulose membrane (BioTraceTM NT, Pall Corporation, FL, USA) were soaked in cold
1×Western Transfer Buffer with 20% methanol and assembled with the gel into a transfer cassette.
Transfer was carried out at 250 mA for 1 h at 4 ◦C. The membrane was blocked in 15% skim milk for
1 h and blotted with primary antibodies against Flii (SC30046, 1 µg/mL Santa Cruz Biotechnologies,
Dallas, TX, USA) and β-tubulin (T8328, 0.4 µg/mL, Sigma-Aldrich, Castle Hill, NSW, Australia) in
6% skim milk overnight at 4 ◦C. The membrane was washed 3 times for 5 min in 1× TBST (TBS,
0.1% Tween20) and probed with secondary antibodies (DAKO P0447 1:2000 and P0448 1:2000, Agilent,
Santa Clara CA, USA) for 1 h at room temperature. The membrane was washed 2 times for 5 min in
1× TBST, once for 5 min in TBS, developed using a Clarity Western ECL kit (Bio-Rad, Gladesville, NSW,
Australia), and imaged under UV light using a SynGene G-Box. Results were representative of three
independent experiments.
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4.11. Statistical Analysis
All analysis was carried out in Graphpad Prism (Graphpad, CA, USA). For histological and
immunohistochemical comparisons between Flii+/−, WT and FliiTg/Tg wounds, statistical significance
was calculated using a 2-way analysis of variance (ANOVA) with multiple comparisons. For in vitro
analyses, statistical significance between treatment groups was calculated using a 2-way ANOVA with
multiple comparisons. Annotation of significance above any time point indicates statistical significance
between the untreated and siFlii groups at the time point. A p-value of <0.05 was considered significant.
All data are displayed as mean ± SEM.
5. Conclusions
Understanding the mechanisms of diabetic repair will be important in the development of
improved therapies to enhance the healing of DFUs. Pericytes are important for the regulation of many
processes commonly dysregulated in diabetic wounds. The data presented here indicates that Flii
regulates pericyte presence and function in diabetic wounds, and illuminates an additional mechanism
by which Flii attenuation can enhance healing outcomes in both acute and diabetic wounds.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/16/5599/
s1. Figure S1 (a) Hematoxylin and Eosin staining of representative Flii+/−, WT and FliiTg/Tg diabetic excisional day
3, 5, 7 and 14 wounds. Wound width indicated by dashed white line. Composite images taken at 10× objective,
scale bar = 0.5 m. (b) Histological wound width measurements of Flii+/−, WT and FliiTg/Tg diabetic excisional day
3, 5, 7 and 14 wounds. Data displayed as mean ± SEM, n = 8. (c) Histological measurement of re-epithelialisation
represented as % of total epithelial length. Data displayed as mean ± SEM, n = 8. Statistical significance was
calculated using a two-way ANOVA where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Figure S2.
(a) Immunohistochemical detection and quantification of collagen I in 4 µm sections of paraffin-embedded diabetic
Flii+/−, WT and FliiTg/Tg wounds. (b) Immunohistochemical detection and quantification of collagen III in 4 µm
sections of paraffin-embedded diabetic Flii+/−, WT and FliiTg/Tg wounds. Images taken at 20× objective, scale
bar = 50 µm. Data displayed as mean ± SEM, n = 7. Statistical significance was calculated using a two-way
ANOVA where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
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BGL Blood glucose level
DFUs Diabetic foot ulcers
Flii Flightless I
Flii+/− Flightless I heterozygous knockout
FliiTg/Tg Flightless I transgenic overexpressing
FnAb Flii neutralizing antibody
HDMEC Human dermal microvascular endothelial cells
hPC-PL Human Pericytes from Placenta
Int. J. Mol. Sci. 2020, 21, 5599 13 of 15
IL-10 Interleukin-10
LER Low expression regions
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MSC Mesenchymal stem cell
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PDGFRβ Platelet-derived growth factor receptor beta
STZ Streptozotocin
TNF Tumour necrosis factor
VEGF Vascular endothelial growth factor
Appendix A. Animal Studies
Appendix A.1. Sample Size Determination
The sample size for the mouse studies was calculated using G power. A reduction in surface area of 20% or
more was considered biologically significant. Power studies for the diabetic mouse model showed that a sample
size of 8 would give 90% power using a 5% test level and a one-tailed test.
Appendix A.2. Murine Model of Inducible Diabetes
Prior to injection, mice were fasted for 4 h, after which each mouse received an intraperitoneal injection of a
previously optimised low dose of streptozocin (STZ) (50 mg/kg) for 5 consecutive days [14]. Non-diabetic control
mice were similarly fasted and received equivalent injections of vehicle only to serve as a control. Following the
commencement of injections, mice were observed twice daily and weighed daily for the first 3 days, after which
observation continued once daily. Tail vein sampling was used to monitor non-fasting blood glucose levels (BGL)
every 2–3 days for 4 weeks following the culmination of STZ injections. After these 4 weeks had elapsed, animals
with confirmed diabetes (as indicated by a BGL of greater than 15 mmol/L) were administered a subcutaneous
injection of insulin (2 IU) every second day to maintain body weight and prevent ketoacidosis. Any animals which
failed to maintain a weight within 10% of their starting weight or display BGL elevated above 25 mmol/L received
an increased dose of 4 IU insulin every second day. Mice were maintained on this regimen for a further 2 weeks,
after which mice with confirmed hyperglycaemia (BGL greater than 15 mmol/L) were subjected to the excisional
wound model, while mice failing to display hyperglycaemia were excluded from progressing further in the study
at this point. In keeping with the three Rs (Replacement, Refinement and Reduction), and in preference to the
induction of new mice, previously induced mice which did not exhibit hyperglycaemia after 6 weeks received a
‘re-induction’ protocol of 50 mg/kg STZ IP injection for a further 5 days. The induction rates following re-induction
were significantly elevated in all genotypes.
Appendix A.3. Murine Model of Excisional Wound Healing
In accordance with WCH animal ethics approval (AE1021/10/18), diabetic Flii+/−, WT and FliiTg/Tg mice
were subjected to a model of excisional wound healing. Prior to wound induction, diabetic mice were housed
in smooth-bottom plastic cages with paper bedding and free access to water and rodent food pellets (22 ◦C and
12 h dark/light cycle). Environment enrichments were provided by adding clean toilet rolls and toys to the cages
to prevent stress and boredom. Mice were anaesthetised by inhalation of 5% isoflurane (Abbott Australasia,
NSW, Australia) and 5% oxygen at 2 L/min for induction and maintained at 2% isoflurane with 2% oxygen at
700 mL/min of maintenance. Prior to surgery, analgesia (Buprenorphine at 0.05 mg/kg, MSD, NSW, Australia) was
administered to each mouse. The dorsal surface of the mice was shaved and depilated. Six mm punch biopsies
(EBOS, NSW, Australia) were used to create two 6 mm2 full-thickness excisional wounds on the dorsal surface of
the mice 5 mm either side of the midline and 10 mm from the base of the skull. Mice were allowed to recover from
anaesthesia on a heated pad, after which they were returned to individual cages and allowed to recover in a warm,
dry cage with water and food ad libitum. Wounds were collected 3, 5, 7 or 14 days post-surgery and wound
samples were fixed in 10% neutral buffered formalin overnight, transferred to 70% ethanol for 24 h, embedded in
paraffin wax and sectioned for analysis (n = 8 mice, 16 wounds for each genotype at each timepoint).
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